Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Wuhan Keqian Biology CoSHSE:688526 +0.56%80 EBITDA Margin % is 39.63% as of Mar. 2026, which is 35% below its 10-year median of 60.97. GuruFocus rates SHSE:688526 with a GF Score™ of 80/100 and a GF Value™ of ¥16.91 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 940 Biotechnology companies, Wuhan Keqian Biology Co ranks better than 93.4% on this metric.
Wuhan Keqian Biology Co (SHSE:688526) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Wuhan Keqian Biology Co EBITDA Margin % Related Terms
Wuhan Keqian Biology Co EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:688526 vs VRTX, REGN, ALNY: EBITDA Margin % Comparison
For the Biotechnology subindustry, Wuhan Keqian Biology Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Wuhan Keqian Biology Co EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Wuhan Keqian Biology Co's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Wuhan Keqian Biology Co's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Wuhan Keqian Biology Co (SHSE:688526) has a EBITDA Margin % of 39.63% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Wuhan Keqian Biology Co and its competitors. This is 35% below median its historical median of 60.97. Over the past decade, Wuhan Keqian Biology Co's EBITDA Margin % has ranged from 47.68 to 66.07. According to the industry distribution chart, Wuhan Keqian Biology Co ranks #62 out of 940 companies in the Biotechnology industry, placing it in the top 6.6%.
Is Wuhan Keqian Biology Co's EBITDA Margin % too high?
Wuhan Keqian Biology Co's current EBITDA Margin % of 39.63% is 35% below median its 10-year median of 60.97. Over the past 10 years, this metric has ranged from a low of 47.68 to a high of 66.07. Based on the distribution chart, Wuhan Keqian Biology Co ranks #62 out of 940 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Wuhan Keqian Biology Co has a GF Score™ of 80/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Wuhan Keqian Biology Co's EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Wuhan Keqian Biology Co ranks #62 out of 940 companies for EBITDA Margin %. This places Wuhan Keqian Biology Co in the top 7% of its industry — outperforming the majority of peers. Historically, Wuhan Keqian Biology Co's own EBITDA Margin % has ranged from 47.68 to 66.07 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Wuhan Keqian Biology Co and its competitors. Wuhan Keqian Biology Co's current EBITDA Margin % is 39.63%, which is 35% below median its own 10-year median of 60.97. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Wuhan Keqian Biology Co stock overvalued right now?
Based on GuruFocus' analysis, Wuhan Keqian Biology Co (SHSE:688526) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥16.91, compared to a current price of ¥12.65 — trading 25.2% below its estimated fair value. The current EBITDA Margin % is 39.63%, which is 35% below median its 10-year median of 60.97. Wuhan Keqian Biology Co's overall GF Score™ is 80/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Wuhan Keqian Biology Co (SHSE:688526), the current EBITDA Margin % is 39.63% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Wuhan Keqian Biology Co (SHSE:688526) Overvalued in 2026?
Based on GuruFocus' analysis, Wuhan Keqian Biology Co stock appears to be undervalued.
The current stock price of ¥12.65 is trading 25.2% below its estimated GF Value™ of ¥16.91.
GuruFocus considers Wuhan Keqian Biology Co to be Modestly Undervalued.
Key valuation signals for SHSE:688526:
EBITDA Margin %: 39.63% (35% below median its 10-year median of 60.97)
GF Value™: ¥16.91 vs. price of ¥12.65 (25.2% below fair value)
No single metric tells the full story. See the SHSE:688526 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Wuhan Keqian Biology Co Ltd is engaged in research and development, production, sales and animal epidemic prevention technical services of veterinary biological products. The company's products include Combination plan; Vaccine for swine; Poultry vaccine; Pet vaccine; and Diagnostic reagent.
80GF Score
Get the complete analysis for SHSE:688526
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688526 has been successfully added to your 
